What is ALS Phase II NOG112264 Study (Ozanezumab)?

Category: Others

true

Generic name: Ozanezumab

This is a clinical trial evaluating the safety and efficacy of intravenous ozanezumab (also known as GSK1223249) when compared to placebo in subjects with Amyotrophic Lateral Sclerosis (ALS). Clinical Trial Identifier: NCT01753076

Last updated:
There are no evaluations for ALS Phase II NOG112264 Study (Ozanezumab).